Bibliography
- GROZINGER CM, SCHREIBER SL: enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. (2002) 9(1):3–16.
- ••Excellent review article on HDAC familyenzymes.
- FISCHER DD, CAI R, BHATIA U et al.:Isolation and characterization of a novel class II histone deacetylase, HDAC10. J. Biol. Chem. (2002) 277(8):6656–6666.
- GAOL, CUETO MA, ASSELBERGS F, ATADJA P: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. j Biol. Chem. (2002) 277(28):25748–25755.
- FINNIN MS, DONIGIAN JR, COHEN A al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 401(6749):188–193.
- •First X-ray crystallography study on a bacterial HDAC homologue.
- JUNG M: Inhibitors of histone deacetylase new anticancer agents. Curt: Med. Chem.(2001) 8(12):1505–1511.
- ••Excellent review article on small moleculeHDAC inhibitors.
- MEINKE PT, LIBERATOR P: Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curt: Med. Chem. (2001) 8(2):211–235.
- FURUMAI R, KOMATSU Y, NISHINO N, KHOCHBIN S, YOSHIDA M, HORINOUCHI S: Potent histone deacetylase inhibitors built from trichostatin A and cyclic antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA (2001) 98(1):87–92.
- ATADJA PW, REMISZEWSKI S, LASSOTA P et al.: In vitro and in vivo properties of LQ824, a novel histone deacetylase inhibitor. Proc. 93rd Ann. Meeting Amer. Assoc. Cancer Res, San Francisco, USA (2002) Abstract 347.
- GLASER KB, LI J, AAKRE ME et al: Transforming growth factor 13 mimetics: discovery of 7- [4- (4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase. Ma Cancer The]: (2002) 1(10):759–768.
- SU GH, SOHN TA, RYU B, KERN SE: A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. (2000) 60(12)3137–3142.
- HOFFMANN K, BROSCH G, LOIDL P, JUNG M: A non-isotopic assay for histone deacetylase activity. Nucl. Acid Res (1999) 27(9):2057–2058.
- •This paper describes a simple,-radioactive assay for high-throughput screening of HDAC inhibitors.
- SANDOR V, BAKKE S, ROBEY RW et al.: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. (2002) 8(3):718–728.
- PIEKARZ R, ROBEY R, SANDOR V et al.: Potential value of the histone deacetylase inhibitor depsipeptide (FR901228) in the treatment of peripheral and cutaneous T cell lymphoma. Proc. AACR-NCI-EORTC Int. Conf. Mel Targets Cancer Ther: Discovery, Biology and Clinical Applications, Miami Beach, USA (2001) Abstract 360.
- WEIDLE UH, GROSSMANN A: A inhibition of histone deacetylase: a new strategy to target epigenetic modifications for anticancer treatment. Anti-cancer Res. (2000) 20(3A):1471–1485.
- ••Excellent review article describing HDACinhibition as a new strategy for anticancer therapy.
- MARKS PA, RICHON VM, RIFKIND RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.' Nati Cancer Inst. (2000) 92(15):1210–1216.
- ••Excellent review article describing a potentialutility of HDAC inhibitors as a new class of anticancer agents.
- LUO J, SU F, CHEN D, SHILOH A, GU W: Deacetylation of p53 modulates its effects on cell growth and apoptosis. Nature (2000) 408(6810):377–381.
- HUBBERT C, GUARDIOLA A, SHAO R et al: HDAC6 is a microtubule-associated deacetylase. Nature (2002) 417(6887):455–458.